Stokes Capital Advisors Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$3.37M |
| 2 |
Target
TGT
|
+$3.17M |
| 3 |
Vanguard Short-Term Bond ETF
BSV
|
+$2.98M |
| 4 |
NextEra Energy
NEE
|
+$2.47M |
| 5 |
Procter & Gamble
PG
|
+$2.39M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Intermediate-Term Bond ETF
BIV
|
+$3.75M |
| 2 |
Becton Dickinson
BDX
|
+$2.56M |
| 3 |
Colgate-Palmolive
CL
|
+$2.29M |
| 4 |
American Tower
AMT
|
+$1.59M |
| 5 |
Danaher
DHR
|
+$1.29M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.93% |
| 2 | Consumer Staples | 11.24% |
| 3 | Industrials | 11.06% |
| 4 | Healthcare | 10.81% |
| 5 | Financials | 10.21% |
Similar funds
Stokes Capital Advisors's Q1 2021 Portfolio in Review
As of Q1 2021, Stokes Capital Advisors held 70 positions worth $244M, up 6.2% from $230M the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Stokes Capital Advisors deployed $9.05M of net new capital in Q1 2021, opening 1 new position and adding to 50 existing holdings. Its largest new stake was Pfizer: 94,996 shares worth $3.44M.
By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 13% a quarter earlier, followed by Consumer Staples and Industrials.
On the sell side, the largest reduction was Vanguard Intermediate-Term Bond ETF, an estimated $3.75M trimmed.
- Stokes Capital Advisors's largest Q1 2021 buy was Pfizer: 94,996 shares worth $3.44M.
- Stokes Capital Advisors added most to Target in Q1 2021, an estimated $3.17M increase.
- Stokes Capital Advisors's biggest Q1 2021 reduction was Vanguard Intermediate-Term Bond ETF, cutting an estimated $3.75M.
- Stokes Capital Advisors fully exited Becton Dickinson in Q1 2021, selling an estimated $2.56M.
- Stokes Capital Advisors's ten largest holdings make up 30% of its $244M portfolio in Q1 2021.
- Stokes Capital Advisors opened 1 new position and closed 3 in Q1 2021.
- Stokes Capital Advisors's portfolio value rose 6.2% quarter-over-quarter to $244M.
Based on Stokes Capital Advisors's 13F filing for Q1 2021, filed 19 Apr 2021.